Skip to content
Screener

Rhythm Pharmaceuticals, Inc. RYTM Total costs & expenses

Total costs & expenses at other companies

TG Therapeutics logo
TG TherapeuticsTGTX
$218.66M+106%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$300.47M+36.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$46.93M+15.7%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$21.05M-13.1%
XER
Xeris Biopharma Holdings, Inc.XERS
$86.93M+29.6%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$7.62B+27.5%
Enterprise value$7.67B+28.8%
P/S35.1×-3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-030549
Line itemThree months ended March 31, 20262025
Cost of sales7,1573,648
Research and development41,72536,973
Selling, general, and administrative63,59139,087
Total costs and expenses112,47379,708
Loss from operations(52,361)(47,004)
Other income (expense):
Other income (expense), net(1,704)(644)
Interest expense(4,583)(5,409)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Rhythm Pharmaceuticals, Inc.'s total costs & expenses?
Rhythm Pharmaceuticals, Inc. (RYTM) reported total costs & expenses of $112.47M in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s total costs & expenses changed year-over-year?
Rhythm Pharmaceuticals, Inc.'s total costs & expenses increased by 41.1% year-over-year, from $79.71M to $112.47M.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s total costs & expenses?
Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s total costs & expenses has grown at a 21.8% compound annual growth rate (CAGR), from $173.21M to $381.77M.
What does total costs & expenses mean?
This metric represents the aggregate sum of all operating and non-operating costs incurred by the company to support its business activities during a specific period. It encompasses cost of goods sold, research and development expenditures, and selling, general, and administrative expenses. Monitoring this total provides insight into the company's overall cost structure and operational efficiency.

Ask your AI about Rhythm Pharmaceuticals, Inc.'s total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude